Pharmaxis banks
Tuesday, 16 September, 2008
Pharmaxis [ASX: PXL] ended FY08 in a strong cash position despite large R&D-related losses for the financial year.
At the end of FY08 Pharmaxis had $112 million in the bank, significantly higher than the $76 million cash position the company reported in 2007.
But the company posted a loss of around $20 million for the financial year, largely due to research and development costs.
This R&D spend includes two projects currently progressing their way through clinical trials.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
